| Therapeutic Area | Formulary Choices | Cost for 28 (unless otherwise stated) | Rationale for decision / comments |
|---|---|---|---|
| Related guidance: NICE CG137 The Epilepsies: diagnosis and management in adults and children in primary and secondary care Updated Feb 2016 NICE pharmacological treatments |
|||
| MHRA advice in 2103 stated Category 1 – phenytoin, carbamazepine, phenobarbital, primidone For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product i.e prescibe by brand name Category 2 – valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate For these drugs, the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history Category 3 - levetiracetam, lacosamide, tiagabine, gabapentin, pregabalin, ethosuximide, vigabatrin For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors |
|||
